Pubblicazioni

Autori:

Sotirchos, Elias S; Vasileiou, Eleni S; Salky, Rebecca; Huda, Saif; Mariotto, Sara; Chen, John J; Levy, Michael

Titolo:

Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin

Anno:

2022

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

Sì

Nome rivista:

MULTIPLE SCLEROSIS AND RELATED DISORDERS

ISSN Rivista:

2211-0348

N° Volume:

57

Numero o Fascicolo:

103462

Intervallo pagine:

1-3

Parole chiave:

myelin oligodendrocyte glycoprotein antibody associated disease; MOGAD; relapse; subcutaneous Ig (SCIG); treatment

Breve descrizione dei contenuti:

Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.

Pagina Web:

https://doi.org/10.1016/j.msard.2021.103462

Id prodotto:

123758

Handle IRIS:

11562/1053962

ultima modifica:

15 novembre 2022

Citazione bibliografica:

Sotirchos, Elias S; Vasileiou, Eleni S; Salky, Rebecca; Huda, Saif; Mariotto, Sara; Chen, John J; Levy, Michael, Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin «MULTIPLE SCLEROSIS AND RELATED DISORDERS» , vol. 57 , n. 103462 , 2022 , pp. 1-3

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo